Search International and National Patent Collections

1. (WO2018182301) PHARMACEUTICAL COMPOSITION FOR PREVENTION OR TREATMENT OF INFLAMMATORY RESPIRATORY DISEASE, WITH FUSION PROTEIN OF CELL PERMEABLE PEPTIDE AND CTCTLA4 PEPTIDE CONTAINED AS EFFECTIVE INGREDIENT THEREIN

Pub. No.:    WO/2018/182301    International Application No.:    PCT/KR2018/003622
Publication Date: Fri Oct 05 01:59:59 CEST 2018 International Filing Date: Wed Mar 28 01:59:59 CEST 2018
IPC: A61K 38/16
A61K 9/00
Applicants: IUCF-HYU (INDUSTRY-UNIVERSITY COOPERATION FOUNDATION HANYANG UNIVERSITY)
한양대학교 산학협력단
Inventors: CHOI, Je-Min
최제민
LIM, Sangho
임상호
Title: PHARMACEUTICAL COMPOSITION FOR PREVENTION OR TREATMENT OF INFLAMMATORY RESPIRATORY DISEASE, WITH FUSION PROTEIN OF CELL PERMEABLE PEPTIDE AND CTCTLA4 PEPTIDE CONTAINED AS EFFECTIVE INGREDIENT THEREIN
Abstract:
The present invention relates to a pharmaceutical composition comprising a fusion protein as an effective ingredient for prevention or treatment of an inflammatory respiratory disease, wherein the fusion protein has a cell permeable peptide fused with the ctCTLA4 peptide. In an administration manner via a respiratory route through which an effective therapeutic or prophylactic effect has not been conventionally achieved, the present invention has a remarkably outstanding permeability and efficiency to bronchial and pulmonary cells and remarkably improved activity of suppressing cytokine expression and airway inflammation, alleviating hypersensitive responses of the airway to allergens and Th2 inflammation, etc., compared to conventional therapeutic agents for inflammatory respiratory diseases, inter alia, allergic asthma. Therefore, the present invention can bring about a prompt, rapid, and efficient therapeutic or prophylactic effect.